ReviewHormones & cancer2011
The Weiss score and beyond--histopathology for adrenocortical carcinoma.
Review in Hormones & cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).Journal of endocrinological investigation · 2016Guideline
- A Phase II Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Adrenocortical Carcinoma.The Journal of surgical research · 2018Trial
- Adrenocortical Carcinoma with Suspected Dual Cortisol and Aldosterone Secretion: A Case Report.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Analysis of clinical and pathological characteristics of classic adrenocortical carcinoma.Scientific reports · 2026Article
- Article
- Current clinical management and outcome of patients with adrenal cortical carcinoma (ACC) with rare histological subtypes-an ENSAT cohort study.ESMO open · 2026Observational
- Massive non-functioning Adrenocortical carcinoma presenting as acute abdomen without rupture: A case report.Urology case reports · 2026Article
- Adrenal oncocytoma: a rare presentation of a benign 18 F-fluorodeoxyglucose PET avid virilising adrenal tumour.Nuclear medicine communications · 2025Article
- Updates on WHO 5th edition classification, molecular characteristics and tumor microenvironment of adrenocortical carcinomas.Endocrine journal · 2025Review
- A rare manifestation of adrenocortical carcinoma as a mimic of pheochromocytoma: a case report and literature review.Frontiers in endocrinology · 2025Review
- Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches.The oncologist · 2024Review
- Review of Diagnostic Modalities for Adrenal Incidentaloma.Journal of clinical medicine · 2023Review
- A rare case of co-secreting adrenocortical oncocytoma.Urology case reports · 2023Article
- Establishment of Rat Model of Female Genital Sexual Arousal Disorder.Sexual medicine · 2022Article
- Is the Adrenal Incidentaloma Functionally Active? An Approach-To-The-Patient-Based Review.Journal of clinical medicine · 2022Review
- Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.The Journal of clinical endocrinology and metabolism · 2022Review
- Revisiting the AJCC staging system of adrenocortical carcinoma.Journal of endocrinological investigation · 2022Article
- Was It an Adrenocortical Adenoma or an Adrenocortical Carcinoma? Limitation of the Weiss Scoring System in Determining the Malignant Potential of Adrenocortical Tumor: Report on Two Cases.Case reports in endocrinology · 2022Article
- Oncocytic Adrenocortical Carcinoma With LowJournal of the Endocrine Society · 2021Article
- Case report: A giant hemorrhagic adrenocortical carcinoma causing cardiorespiratory embarrassment.Annals of medicine and surgery (2012) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathological diagnosis of adrenocortical carcinoma (ACC) is still challenging for its rarity and the presence of special variants (pediatric, oncocytic, myxoid, and sarcomatoid). It is based on the recognition at light microscopy of at least three among nine morphological parameters, according to the Weiss scoring system, which has been introduced 27 years ago and nowadays is the most widely employed. Nevertheless, the diagnostic performance of this system is very high but does not reach a sensitivity and specificity of 100%, its diagnostic applicability is potentially low among non-expert pathologists, and a group of borderline cases with only one or two criteria exist of uncertain behavior. Moreover, it is scarcely reproducible in the ACC morphological variants. In fact, specifically for the pure oncocytic neoplasms that seem to have a better prognosis in comparison to the conventional ACCs, a modified system (the Lin-Weiss-Bisceglia) has been proposed. With the aim to simplify the ACC diagnosis, 2 years ago, the "reticulin" diagnostic algorithm has been proposed, based on the observation that the tumoral reticulin framework (highlighted by reticulin silver-based histochemical staining) is consistently disrupted in malignant cases but only in a small subset of benign cases. Following this algorithm, in the presence of reticulin alterations, malignancy is further defined through the identification of at least one of the following parameters: necrosis, high mitotic rate, and venous invasion. As a complement to the morphological approach, some immunohistochemical markers (such as steroidogenic factor 1) have been proposed as diagnostic and prognostic adjuncts but still lack wide clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.